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Abstract  
INTRODUCTION: Renal transplantation became a routine and successful medical treatment for Chronic Kidney 
Disease in the last 30 years all over the world. Introduction of Luminex based Single Antigen Beads (SAB) and 
recent BANFF consensus of histopathological phenotypes of different forms of rejection enables more precise 
diagnosis and changes the therapeutic approach. The graft biopsies, protocol or cause, indicated, remain a 
golden diagnostic tool for clinical follow up of kidney transplant recipients (KTR). 
AIM: The study aimed to analyse the histopathological changes in renal grafts 12 months after the surgery in KTR 
with satisfactory kidney function. 
MATERIAL AND METHODS: A 12-month protocol biopsy study was performed in a cohort of 50 Kidney 
transplant recipients (42 from living and 8 from deceased donors). Usual work-up for suitable donors and 
recipients, standard surgical procedure, basic principles of peri and postoperative care and follow up were done in 
all KTR. Sequential quadruple immunosuppression including induction with Anti-thymocyte globulin (ATG) or 
Interleukin-2R antagonist (IL-2R), and triple drug maintenance therapy with Calcineurin Inhibitors (CNI), 
Mycophenolate Mofetil (MMF) and Steroids were prescribed to all pts. Different forms of Glomerulonephritis (16), 
Hypertension (10), End Stage Renal Disease (13), Hereditary Nephropathies (6), Diabetes (3) and Vesicoureteral 
Reflux (2) were the underlying diseases. All biopsies were performed under ultrasound guidance. The 16 gauge 
needles with automated “gun” were used to take 2 cores of tissue. The samples were stained with HE, PAS, 
Trichrome Masson and Silver and reviewed by the same pathologist. A revised and uploaded BANFF 2013 
classification in 6 categories (Cat) was used. 
RESULTS: Out of 48 biopsies, 15 (31%) were considered as normal, 4 (8%), Borderline (BL-Cat 3), 5 (10%) as 
Interstitial Fibrosis/Tubular Atrophy (IF/TA-Cat 5), 5 (10%) were classified as non-immunological (Cat 6), 2 as a 
pure antibody-mediated rejection (ABMR-Cat 2) and T-cell Mediated Rejection (TCMR-Cat 4). The remaining 17 
samples were classified as a “mixed” rejection: 7 (41%) ABMR + IF/TA, 5 (29%) ABMR + BL + IF/TA, 2 (11%) BL 
+ IF/TA, 1 (5%) ABMR + BL, 1 (5%) ABMR + TCMR and 1 (5%) TCMR +  IF/TA. The mean serum creatinine at 
the time of the biopsy was 126.7 ± 23.4 µmol/L, while GFR-MDRD 63.4 ± 20.7 ml/min, which means that the 
majority of the findings were subclinical. Among the non-immunological histological findings (Cat 6), 3 cases 
belonged to CNI toxicity, 1 to BK nephropathy and 1 to recurrence of the primary disease.  
CONCLUSION: Our 12-month protocol biopsy study revealed the presence of different forms of mixed subclinical 
rejection. Use of recent BANFF classification and scoring system enables more precise diagnosis and 
subsequently different approach to the further treatment of the KTR. More correlative long-term studies including 
Anti HLA antibodies and Endothelial Cell Activation- Associated Transcripts (ENDAT) are needed. 
 
 
Introduction 
 
Kidney transplantation is an incredible 
success of modern medicine. The better 
understanding of the basic immunological mechanism 
and the introduction of some new molecules in 
everyday practice enables improved long-term graft 
and patient’s survival, better quality of life and 
practically uneventful clinical course for many years 
[1] [2] [3] [4]. According to the recent data, 20 years 
graft survival could be expected in 60% of kidney 
transplant recipients [5] [6]. However, there are still 
unsolved problems and questions that remain to be 
investigated from the scientific and practical point of 
view. One of the major causes of graft loss is still a 
rejection, either cellular or humoral. It has been 
accepted today that approximately 60% of the long-
term graft loss belongs to the acute or chronic 
antibody-mediated rejection (ABMR) [7] [8] [9] [10] 
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The introduction of some new diagnostic tools such as 
Luminex based Single Antigen Beads (SAB), enables 
to detect a huge amount of anti HLA antibodies, non 
HLA antibodies and some fraction of activated 
complement system. The presence of anti HLA 
antibodies, especially Donor Specific Antibodies 
(DSA) in the patient’s sera leads to chronic allograft 
nephropathy and long-term graft loss [11] [12] [13].  
Thus, overcoming kidney allograft rejection 
could have a beneficial effect on long-term graft 
survival. However, other important pathological 
features rated as CNI toxicity, BK nephropathy, and 
recurrence of the primary kidney disease have also a 
substantial impact on the graft survival rate [14]. 
Despite modern diagnostic procedures implemented 
in everyday clinical practice, the kidney allograft 
biopsy remains a gold standard to determine the 
cause of graft dysfunction. Biopsy findings change the 
clinical diagnosis in an average of 36% of patients 
(range 24-76) and immunosuppressive therapy in 
59% [15] [16]. But, the allograft biopsy does not 
contribute only to clinical diagnosis. It could also be 
used as a prognostic marker and guide to individual 
therapeutic approach to different patients [17] [18]. 
The development of so-called Banff scoring system in 
the last 25 years enables a much better 
understanding what is happening inside of the grafts 
[19] [20]. Introduction of the protocol biopsies gave 
very useful information about relevant 
histopathological changes in patients without any 
clinical evidence of graft dysfunction. They created 
practically new pathological entity named “subclinical 
acute or chronic rejection” which was very important 
regarding possible treatment and further clinical 
course of transplant recipients [21] [22] [23]. It is true 
that in the new era of potent immunosuppression 
therapy, the frequency of acute cellular or antibody-
mediated rejection falls between 8-12 % and, 
therefore, the use protocol biopsies became a little bit 
controversial, but they are still very useful regarding 
treatment changes or individual approach to different 
patient circumstances. In any case, either protocol or 
clinically indicated, allograft biopsy is a condition sine 
qua non for modern clinical follow up of any organ 
transplant patient [24] [25] [26]. 
The study aimed to analyse the 
histopathological changes in renal grafts 12 months 
after the surgery in KTR with satisfactory kidney 
function.  
 
 
Material and Methods 
 
Forty-eight successful biopsied patients with 
haploidentical living (40) and 8 deceased donor 
transplantation were included in a 12-month 
prospective study. Renal transplantation was 
performed at the University Clinical Centre Mother 
Teresa-Skopje, Republic of  Macedonia, by the well-
known principles from the surgical and nephrological 
aspect. Hypertension, Glomerulonephritis, Hereditary 
nephropathies and End Stage Renal Disease (ESRD) 
were predominant underlying kidney diseases. 
Standard pre-transplant workup was done to all 
potential donors and recipients.  
Table 1: Updated 2013 Banff classification categories 
1. Normal 
2. Antibody-mediated 
Acute/active ABMR; all three features must be present for a diagnosis 
1. Histologic evidence of acute tissue injury, including one or more of the 
following: 
 Microvascular inflammation (g > 0 and/or ptc > 0) 
Intimal or transmural arteritis (v > 0) 
 Acute thrombotic microangiopathy, in the absence of any other 
cause 
2. Evidence of current/recent antibody interaction with vascular 
endothelium, including at least one of the following: 
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF 
on frozen              sections, or C4d > 0 by IHC on paraffin sections) 
 At least moderate microvascular inflammation ([g +ptc] > 2) 
 Increased expression of gene transcripts in the biopsy tissue 
indicative of endothelial injury if thoroughly validated 
3. Serologic evidence of donor-specific antibodies (DSAs) (HLA or 
other antigens) 
 Chronic, active ABMR; all three features must be present for a diagnosis 
1. Morphologic evidence of chronic tissue injury, including one or more 
of the following: 
 Transplant glomerulopathy (TG) (e.g.> 0), if no evidence of chronic 
thrombotic microangiopathy Severe peritubular capillary basement 
membrane multilayering (requires EM) 
 Arterial intimal fibrosis of new onset, excluding other causes 
2. Evidence of current/recent antibody interaction with vascular 
endothelium, including at least one of the following: 
 Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF 
on frozen sections, or C4d > 0 by IHC on paraffin sections) 
 At least moderate microvascular inflammation ([g +ptc] > 2) 
 Increased expression of gene transcripts in the biopsy tissue 
indicative of endothelial injury, if thoroughly validated 
3. Serologic evidence of DSAs (HLA or other antigens) 
 C4d staining without evidence of rejection; all three features must be present for 
a diagnosis 
1. Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by 
IF on frozen sections, or C4d > 0 by IHC on paraffin sections) 
2. g = 0, ptc = 0, eg = 0 (by light microscopy and by EM if 
available), v = 0; no TMA, no peritubular capillary basement membrane 
multilayering, no acute tubular injury (in the absence of another apparent 
cause for this) 
3. No acute cell-mediated rejection (Banff 97 type 1A or greater) 
or borderline changes 
 
3.  Borderline changes: ‘Suspicious’ for acute T-cell mediated rejection (may 
coincide with categories 2 and 5, and 6) 
This category is used when no intimal arteritis is present, but there are foci of tubulitis 
(t1, t2, or t3) with minor interstitial infiltration (i0, or i1) or interstitial infiltration (i2, i3) 
with mild (t1) tubulitis 
4. T cell-mediated rejection (TCMR, may coincide with categories 2 and 5 and 6) 
             Acute T-cell mediated rejection (Type/Grade:) 
              I A. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 
or i3) and foci of moderate tubulitis (t2) 
              I B. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 
or i3) and foci of severe tubulitis (t3) 
              II A. Cases with mild to moderate intimal arteritis (v1) 
              II B. Cases with severe intimal arteritis comprising >25% of the luminal area (v2) 
              III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of 
medial smooth muscle cells with accompanying lymphocytic inflammation (v3) 
             Chronic active T-cell mediated rejection 
            ‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell 
infiltration in fibrosis, the formation of neo-intima) 
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific aetiology 
    (may include nonspecific vascular and glomerular sclerosis, but severity graded by 
tubulointerstitial features) 
            I. Mild interstitial fibrosis and tubular atrophy (>25% of cortical area) 
            II. Moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) 
            III. Severe interstitial fibrosis and tubular atrophy/loss (>50% of cortical area) 
6. Other: Changes not considered to be due to rejection-acute and/or chronic 
Cg, Banff chronic glomerulopathy score; EM, electron microscopy; ENDAT, endothelial 
activation and injury transcript; g, Banff glomerulitis score; GBM, glomerular basement 
membrane; IF, immunofluorescence; IHC, immunohistochemistry; ptc, peritubular 
capillary; TCMR. T cell-mediated rejection; v. Banff arteritis score. 
 
According to the centre policy, 50% was a 
minimum accepted HLA matching in both, living and 
deceased donor transplantation. A sequential 
quadruple Immunosuppression including ATG or      
IL-2R antagonist induction and Prednisolone, MMF 
and CNI as a triple-drug maintenance therapy was 
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introduced to all recipients. After the surgery, the 
patients were followed by the same team according to 
the KDIGO recommendations. Usual Lab analyses, 
proteinuria, GFR, trough immunosuppressant levels, 
graft ultrasound tomography including Doppler were 
done practically every month on the outpatient basis.
  
Table 2: Pathological features and Banff score 
Feature 
Banff 
term 
Banff Score 
0 1 2 3 
Interstitial inflammation (% of 
nonfibrotic cortex) 
i <10% 10–25% 26–50% >50% 
Total inflammation (% all cortex) ti <10% 10–25% 26–50% >50% 
Tubulitis (maximum mononuclear 
cells/tubule) 
t 0 1–4 5–10 >10 
Arterial inflammation (% lumen 
endarteritis) 
V None <25% >25% 
Transmural 
or necrosis 
Glomerulitis (% glomeruli involved) g None <25% 26–50% >50% 
Capillaritis (cells per cortical PTC, 
requires >10% of PTC to be affected 
for scoring) 
ptc <10% <5/PTC 5–10/PTC >10/PTC 
C4d deposition in PTC (% positive) C4d 0% l–9% 10–50% >50% 
Interstitial fibrosis (% of cortex) ci <5% 6–25% 26–50% >50% 
Tubular atrophy (% cortex) ct 0% <25% 26–50% >50% 
Arterial intimal thickening (% narrowing 
lumen of most severely affected 
glomerulus) 
cv 0% <25% 26–50% >50% 
Transplant glomerulopathy (% of 
capillaries with duplication in most 
severely affected glomerulus) 
cg 0% <25% 26–50% >50% 
Arteriolar hyalinosis (number with 
focal or circumferential hyaline) 
ah None 1 focal >1 focal 
1 
circumferenti
al >50% 
Mesangial matrix increase (% 
affected glomeruli) 
mm 0% <25% 26–50% >50% 
 
A total of 48 biopsies (one for each patient 
included in the study) were done exactly on the 12
th
 
month after the transplantation. All the biopsies were 
performed under ultrasound guidance 16 gauge 
needle was used with an automated “gun”. Samples 
routinely comprised 2 cores to get a sufficient amount 
of glomeruli. The formalin-fixed biopsies were 
embedded in paraffin, serially sectioned at 3 and 5 µm 
thickness and stained with hematoxylin-eosin (HE), 
Periodic Acid-Schiff (PAS), Masson trichrome as well 
as methenamine silver. Biopsies were considered 
adequate when they contained ≥ 7 glomeruli and at 
least one artery.  
Renal lesions were reviewed for evidence of 
chronic and acute changes by the same pathologist 
using descriptive criteria according to the Banff 2013 
scoring schema using a scale from 0-3. At the same 
time, a frozen section sample was used for 
Complement (C3) immunofluorescence microscopy. 
C4d immunohistochemistry was performed on 3 µm 
thick paraffin sections using “Novolink” Polymer 
detection system with rabbit anti-human C4d 
monoclonal antibody [27] [28]. 
Histological findings were classified into six 
categories according to BANFF 13 modified and 
uploaded system: Normal (category 1), Antibody-
mediated rejection (ABMR category 2), Borderline (BL 
-category 3), T – cell-mediated rejection (TCMR –
category 4), Interstitial fibrosis and tubular atrophy 
(IF/TA-category 5) and other non-immunological 
changes (category 6). The BANFF scoring system 
(from 0-3) was used for the grading of acute and 
chronic changes occurring in the interstitium, tubules, 
glomeruli, arteries and arterioles. For diagnosis of 
ABMR, a revised BANFF 13 criteria which include 
“C4d negative ABMR” were used [29] [30], (Table 1 
and 2). The research was performed following the 
tenets of the Declaration of Helsinki. Informed consent 
was obtained from the patients for the protocol 
biopsies. The research was approved by the Ethical 
Committee of the Medical Faculty Skopje. 
Descriptive statistic was used, frequencies 
and percentages for categorical data; average values 
and standard deviation for continuous data.  
 
 
Results 
 
The demographic and clinical characteristics 
are present in Table 3. 
Table 3: Clinical and demographic data 
Data Number 
Age 34.5 ± 11.7 
Gender W/M 14/37 
Underlying disease 
Glomerulonephritis 
Hereditary Nephropathy 
Hypertension 
Diabetes 
VUR 
ESRD 
 
16 
6 
10 
3 
2 
13 
HLA Missmatch 3.1± 0.4 
Living/deceased donors 40/8 
CIT Living/ deceased donor 3.7 ± 0.3/ 10.4 ± 4.2 
Induction therapy-Sim/ATG 19/31 
Maintenance immunosuppression 
CNI-Cyclosporin/ Tacrolimus 
MMF / Steroids 
 
19/31 
50/50 
Rejection (clinical) 6 (11%) 
Serum creatinine (12 month) 126.7 ± 23.4 
GFR-MDRD (12 month) 63.4 ± 20.7 
VUR – Vesico-ureteral Reflux, ESRD-End Stage Renal Disease, CIT-Cold ischemia time, 
CNI-Calcineurin Inhibitors, MMF-Mycophenolat Acid, Sim-Simulect, ATG – Anti -thimocyte 
Globulin. 
 
A total of 50 biopsies in 50 patients were 
performed. Forty-eight were successful and available 
for analysis (> 8 glomeruli). The histopathological 
findings of the 12
th
 month's protocol biopsies were 
categorised according to the updated Banff 13 scoring 
system. (Table 4). We noticed that only 15 (31%) 
cases belong to the category 1 which means normal 
biopsy. On the other hand, respecting the Banff 2013 
criteria strictly, only 1 as sample could be determined 
as a pure ABMR and one pure TCMR which 
represents 4% of the cases. Five samples were 
classified as IF/TA and other 5 to “others”, which 
mean non-immunological histological changes 
including CNI nephrotoxicity, BK nephropathy or 
recurrence of the primary disease.  
Table 4: Categorization of biopsies according to the updated 
Banff 2013 scoring system (n = 48) 
Banff diagnostic category Number of cases Percentage 
Normal ( Category 1) 15 31 
Pure ABMR ( Category 2) 1 2 
Borderline T-cell rejection (Category 3) 4 8 
T-cell mediated rejection (Category 4) 1 2 
IF/TA (Category 5) 5 10 
Other (Category 6) 5 10 
Mixed 17 35 
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The crucial point of every kidney allograft 
biopsy, protocol or indicated, is the issue of rejection, 
whether cellular or humoral. For TCMR (Cat 4) and 
TCMR borderline rejection (Cat 3) we used Banff 
scoring for interstitial infiltration (i), tubulitis (t) and 
arterial inflammation (v) whereas for ABMR 
glomerulitis (g), transplant glomerulopathy (cg), 
peritubular capillaritis (ptc), arterial inflammation (v), 
tubulitis (t) and positive C4d [31] [32] [33].  
Table 5: Analysis of “mixed” category (n = 17) 
Category Number of cases Percentage % 
ABMR ( Cat 2) + IF/TA (Cat 5) 7 41 
ABMR(Cat 2) + BL ( Cat 3) 1 5 
ABMR ( Cat 2) + BL (Cat 3) + IF/TA ( Cat 5) 5 29 
BL ( Cat 3) + IF/TA ( Cat 5) 2 11 
ABMR ( Cat 2) + TCMR ( Cat 4) 1 5 
TCMR ( Cat 4) + IF/TA 1 5 
 
The rest of kidney biopsies belonged to the 
category of so-called “mixed” rejection which is 
presented in Table 5 and Figure 1.  
 
Figure 1: A: C4d positive immunostaining in peritubular capillaries in acute humoral rejection; B: Chronic 
allograft vasculopathy (arterial blood vessel with fibrointimal thickening); C: CD3 immunostaining for T cell in 
acute cellular mild rejection. (brown - T lymphocytes); D: Acute cellular rejection – tubulointerstitial – grade 
1a: (mild interstitial infiltration and focuses of mild tubulitis > 4 cells cross tubular section/); E: Trichrome 
Masson histochemical staining: IF/TA (Interstitial fibrosis and tubular atrophy) 
 
 
Discussion 
 
ABMR 
According to literature, the frequencies of 
ABMR in biopsies 12 months after transplantation 
differed between patients with/without HLA-DSA 
(0.2% vs 12%). Our results were closer to the protocol 
biopsies in patients without HLA-DSA which is 2.2%. 
Based on the recent BANFF data and a broad 
spectrum of different opinions about the humoral 
rejection, we used so-called “expanded criteria” for 
diagnosis or even “suspicious” for ABMR. It was the 
reason why we had too much of Category 2 (it means 
ABMR) in our analysis presented in Table 5. Certainly 
part of the criteria was also detectable DSA, non-DSA 
or Non -HLA antibodies. Regarding Cd4 and grading 
scores, we accept that presence of C4d was not 
anymore one of the criteria for ABMR. After many 
controversial findings regarding C4d, a revised Banff 
2013 classification included the category of “C4d 
negative ABMR” [29] [30]. Theoretically, it means that 
there are alternative non-complement depending 
reactions of HLA antibodies and graft endothelium. 
The story of ABMR becomes complicated and this 
was shown by the fact that some typical 
histopathological ABMR changes may be seen even if 
HLA and non HLA antibodies exist in the examined 
serum samples. In the Banff 2013 scoring system the 
term borderline or “suspicious” was accepted in the 
criteria for ABMR. It means that suspicious ABMR 
may even exist if only C4d staining is present without 
positive anti HLA antibodies and any other typical 
changes for definitive ABMR [30]. Additionally, any 
simple presence of vascular inflammation could be 
sufficient for the diagnosis of ABMR. Despite the 
different phenotypes, we unified ABMR as one 
category including “suspicious”, acute/active or 
chronic/active forms which facilitated further analysis 
and conclusions [26] [28].  
 
TCMR and Borderline Rejection 
The percentage of pure TCMR was less than 
those in the literature 2% vs 8.2% respectively, but if 
the number is corrected for the numbers of 
“borderline” changes and TCMR in a mixed group, the 
percentage was closer to previous reported. The 
finding of TCMR which was present in different forms 
and phenotypes in 13 of the biopsies was a certainly 
interesting issue: one as a pure TCMR, 4 as a 
Borderline TCMR, 5 as a Borderline together with 
ABMR and IF/TA, and 3 with IF/TA. According to the 
previous Banff session, any classified “borderline” 
changes” should be understood as a rejection and 
should be treated appropriately, especially if there is 
an increase of serum creatinine [29] [30] [42]. 
Moreover, there is evidence that TCMR or borderline 
TCMR can provoke real ABMR and shorten the graft 
survival rate. The presence of some ABMR pattern 
together with TCMR or ‘Borderline” TCMR, also 
deserves attention. Is it evidence that ABMR is 
already activated by TCMR, or it is simply two 
separated parallel findings? We are more inclined to 
the conclusion that, if there is no anti HLA antibodies 
and any C4d activity, it could be evident that TCMR 
had already been initiated ABMR [15] [22] [28]. 
 
Mixed Rejection 
While analysing the findings and classification 
presented in Table 5, we can conclude that in 35% of 
the biopsies there was a broad spectrum of 
histopathological changes which usually does not 
correspond with the clinical picture. Wehmeier et al., 
in their study, reported the percentage of mixed 
rejection in biopsies from 2.6% in patients without 
DSA and 14% in patients with DSA, up to 22% in 
biopsies by indication in DSA patients. Mixed rejection 
means that both TCMR and ABMR with their different 
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sub -phenotypes are equally present in the graft 
biopsy. Potentially it could be quite possible that some 
interactions among them are happening all the time. 
Anyway, we don’t know who came first in the battle, 
but it is quite frequent especially in the protocol 
biopsies. According to the very dynamic issue of 
BANFF meetings and changes which usually come 
every other year, we strongly believe that the 
conclusions are still very far from the real clinical use. 
Bearing in mind that our study is protocol biopsy 
based, most of our cases belong to the entity of 
“subclinical” rejection, or simply, subclinical important 
histopathological changes [22] [28] [34] [35]. It is 
obvious that there are many different pathohistological 
patterns which belong to well-defined forms of 
rejection as ABMR and TCMR but also, at the same 
time, to TCMR-borderline or ABMR “suspicious” 
phenotypes. The recent Banff 2013 recognised so-
called “Chronic active TCMR” which is different than 
the usual acute TCMR with features of chronic 
allograft arteriopathy [30]. Some of the histological 
changes are very similar to ABMR. Thus, it is not easy 
to define “mixed” rejection as an entity not only from 
diagnosis but much more from the point of further 
treatment. Hence, the clinical decision “what to do” if 
there are not sufficient data for definitive diagnosis, 
could be a very complicated issue. Whether these 
changes could have a negative impact on the long-
term clinical outcome or not, it remains to be seen 
after several years.  
 
IF/TA 
In Table 4 and 5, we noted that interstitial 
fibrosis and tubular atrophy is more frequent finding 
compared with others studies. Regarding the severity 
of the IF/TA pathohistological changes in 4 biopsies, 
they were present in more than 50% of active cortical 
tissue, in 13 between 25-50% and only one less than 
25%, which is close to normal. As a pure form, IFTA is 
confirmed in 5 cases, but it was present much more in 
so-called mixed rejection, usually with ABMR (7 
cases), Borderline and ABMR (5 cases), Borderline 
and TCMR (2 cases). IF/TA, especially without 
histological signs of rejection is considered as a 
chronic process [18] [28] [36]. But, the fact that IF/TA 
is the most frequent finding in our 12 months protocol 
biopsy study means that probably it is part of a 
permanent process of rejection, either humoral or 
cellular. The recent gene expression studies 
confirmed that even without histological evidence of 
inflammation IF/TA showed a molecular profile of 
immune-mediated inflammation [37] [38]. In our study, 
we noticed that among the cases in group “mixed”, 7 
(41%) belong to ABMR (Cat 2) and IF/TA (Cat 5). 
Therefore, the finding of any signs of microvascular 
inflammation, and/or active glomerular lesions 
together with IF/TA mean that ABMR was directly 
involved in the interstitial fibrosis. Equally important 
was a possible role of TCMR and Borderline changes 
together with IF/TA [39] [40]. Therefore, interstitial 
fibrosis may be part of broad immunological events, 
especially if DSA or Non-DSA are detectable in the 
patients’ sera. However, the presence of inflammation 
in IF/TA became an unresolved issue even among the 
experts of the Banff group [15] [18] [41]. 
 
Others 
In the final 6
th
 group of biopsies, CNI toxicity 
was a predominant finding, usually as an arterial 
hyalinosis grade 2 or 3. According to the recent 
discussion about the nature of chronic CNI toxicity in 
the era of antibody-mediated rejection, it seems that 
we should strictly divide what CNI toxicity is and what 
ABMR is on the other hand [14]. Especially if the anti 
HLA antibodies are present in the patient's sera. 
Therefore, the chronic CNI toxicity could be simply 
replaced by some of the ABMR phenotypes shortly 
[14]. Until the consensus of that issue is reached, we 
remain on the actual CNI toxicity pattern among our 
biopsies despite the fact that we did not observe any 
potentially toxic CNI level during the 12 months follow 
up. In the last two biopsies of this group, a BK 
nephropathy and FSGS recurrence were diagnosed 
which was also clinically confirmed.  
 
ENDAT 
After all that was presented in our analysis, it 
is evident that additional tests are required to increase 
the prognostic power of pathohistological assessment 
in renal transplant patients. In the last two Banff 
reports, 2013 and 2015, the criteria of “increased 
expression of gene transcripts indicative of endothelial 
injury, if thoroughly validated” was included in the 
whole complicated picture of ABMR. “Thoroughly 
validated” practically means that it should be 
confirmed only in a single centre (University of 
Alberta). Searching for new molecular markers for 
active endothelial injuries the term “ENDAT” 
(Endothelial Cell Activation-Associated Transcripts) 
was broadly introduced [30]. Despite the primary 
confusion in the definition of rejection as a whole 
process, the recent data fully justified gene transcripts 
as a relevant diagnostic tool which should facilitate the 
diagnosis and clinical use of the biopsy as a golden 
standard for kidney graft recipients [37] [39]. 
In conclusion, histologic assessment of kidney 
transplant recipients by use of 12 months protocol 
biopsy revealed a huge amount of different 
histopathological phenotypes and sub-phenotypes of 
ABMR, TCMR and mixed rejection. Most of them were 
clinically silent which was very important for further 
treatment and follow up of kidney transplant 
recipients. Therefore, 12 months protocol biopsies 
together with a strict follow up of anti HLA antibodies 
and clinical picture of kidney transplant recipients is 
necessary for a successful and long-term graft and 
patients survival. 
Severova-Andreevska et al. Spectrum of Histopathological Changes In the Renal Allograft - A 12 Months Protocol Biopsy Study 
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